Lytix Biopharma AS
F:6BG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lytix Biopharma AS
F:6BG
|
NO |
|
Shearwater Group PLC
LSE:SWG
|
UK |
|
Vista Oil & Gas SAB de CV
NYSE:VIST
|
MX |
|
J
|
Japan Airlines Co Ltd
F:JAL
|
JP |
|
Yue Yuen Industrial (Holdings) Ltd
HKEX:551
|
HK |
|
Haugesund Sparebank
OSE:HGSB
|
NO |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
US |
Lytix Biopharma AS
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
